Description
CELLINK SKIN delivers the reliable printability of CELLINK Bioink, enhanced with fibrinogen to support enzymatic crosslinking. After reacting with thrombin, it forms in situ fibrin and fibrinogen, creating a bioactive matrix that resembles the natural skin‑regeneration environment. Formulated with our nanofibrillated cellulose, jointly patented with UPM‑Kymmene, CELLINK SKIN crosslinks easily with CaCl₂ Crosslinking Agent to create stable and supportive constructs.
Specifications
| Appearance | White semi-translucent gel |
| Sterility | Sterile |
| pH |
6.5-7.4 |
| Viscosity | 2.6-7.5 kPa∙s at 0.01 s-1; 1.0-1.9 Pa∙s at 200 s-1 |
| Shelf life | Minimum 3 months |
| Storage conditions | 2-10°C, do not freeze |
| Kit components | CELLINK Skin 3×3 mL cartridge CaCl2 Crosslinking Agent, 45 mL Thrombin |
| Use | For research use only. Not for human use. |
Publications
SARS-CoV-2 infection causes periodontal fibrotic pathogenesis through deregulating mitochondrial beta-oxidation
Gao, Y; Kok, W.L; Sharma, V; Illsley, CS; Hanks, S; Tredwin, C; Hu, B. Cell Death Discovery, 9(1). (2023)
https://doi.org/10.1038/s41420-023-01474-2
Three-Dimensionally Printed Skin Substitute Using Human Dermal Fibroblasts and Human Epidermal Keratinocytes
Patel, J; Willis, J; Aluri, A; Awad, S; Smith, M; Banker, Z; Mitchell, M; Macias, L; Berry, J; King, T. Annals of Plastic Surgery, 86(6S), S628–S631. (2021)
https://doi.org/10.1097/sap.0000000000002886
